MC
HQL

Matisse Capital’s abrdn Life Sciences Investors HQL Stock Holding History

Matisse Capital’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-34,333
Closed -$468K – 187
2024
Q1 		$468K Buy
34,333
+24,333
+243% +$337K 0.23% 126
2023
Q4 		$135K Buy
+10,000
New +$123K 0.07% 191
2021
Q3 		– Sell
-165,000
Closed -$3.54M – 159
2021
Q2 		$3.54M Sell
165,000
-154,311
-48% -$3.12M 1.12% 29
2021
Q1 		$6.29M Hold
319,311
– – 1.81% 12
2020
Q4 		$6.31M Hold
319,311
– – 1.96% 10
2020
Q3 		$5.61M Sell
319,311
-2,957
-0.9% -$53K 2.25% 8
2020
Q2 		$5.79M Buy
322,268
+128,237
+66% +$2.2M 1.92% 12
2020
Q1 		$2.91M Buy
+194,031
New +$3.18M 1.14% 33

Other funds holding HQL

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
AIA
Absolute Investment Advisers Rosemary Beach, Florida $852M AUM 0.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
RL
RPO LLC Stamford, Connecticut $32.3M AUM 14.17% 1-Year Est. Return

Matisse Capital's HQL Position: Q2 2024 in Review

Matisse Capital sold out of abrdn Life Sciences Investors (HQL) in Q2 2024, closing a stake of 34,333 shares — an estimated $468K sold.

Matisse Capital first reported a position in HQL in Q1 2020 and held it in 8 quarters. The position peaked at $6.31M in Q4 2020. 75 funds tracked by Wall St. Rank hold HQL as of Q2 2024.

  • Matisse Capital reported no remaining abrdn Life Sciences Investors position as of Q2 2024 after selling out during the quarter.
  • Matisse Capital sold 34,333 abrdn Life Sciences Investors shares in Q2 2024, an estimated $468K.
  • Matisse Capital first reported a position in abrdn Life Sciences Investors in Q1 2020 and held it in 8 quarters.
  • Matisse Capital's abrdn Life Sciences Investors position peaked at $6.31M in Q4 2020.
  • 75 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2024.

Based on Matisse Capital's 13F filing for Q2 2024, filed 30 Jul 2024.